Disposition of Biologics

Advances in Pharmacology

Volumn 63, Issue , 2012, Pages 257-277

  Brady, Kevin ^a   Webster, Rob ^b  

^a Babraham Research Campus   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINO ACID; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL FACTOR; CYTOCHROME P450; FC RECEPTOR; MONOCLONAL ANTIBODY; NUCLEOTIDE; PEPTIDE; PHOSPHOROTHIOIC ACID; RADIOISOTOPE; SUGAR; THEOPHYLLINE;

ARTICLE; CELLULAR DISTRIBUTION; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; HYDROPHILICITY; IMMUNOGENICITY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL PROCEDURES; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT DNA TECHNOLOGY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SYNTHESIS;

EID: 84863773235     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398339-8.00007-0     Document Type: Chapter

References (27)

1. Andersen J.T., Daba M.B., Berntzen G., Michaelsen T.E., Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. Journal of Biological Chemistry 2010, 285:4826-4836.
2. Andersen J.T., Dalhus B., Cameron J., Daba M.B., Plumridge A., Evans L., et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nature Communications 2012, 3. Article number: 610. 10.1038/ncomms1607.
3. Biron E., Chatterjee J., Ovadia O., Langenegger D., Brueggen J., Hoyer D., et al. Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angewandte Chemie International Edition 2008, 47:2595-2599.
4. 14 C radiolabeling of proteins to monitor biodistribution of ingested proteins. Analytical Biochemistry 2011, 410:57-61.
5. Deen W.M., Satvat B. Determinants of the glomerular filtration of proteins. American Journal of Physiology 1981, 241:F162-F170.
6. Eastwood D., Findlay L., Poole S., Bird C., Wadhwa M., et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. British Journal of Pharmacology 2010, 161:512-526.
7. Garg A., Balthasar J.P. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Journal of Pharmacokinetics and Pharmacodynamics 2007, 34:687-709.
8. 99m Tc-labeling and biodistribution studies of a PNA oligomer containing a new ligand derivative of 2,2'-dipicolylamine. Journal of Inorganic Biochemistry 2010, 104:1133-1140.
9. Graham M.J., Crooke S.T., Monteith D.K., Cooper S.R., Lemonidis K.M., Stecker K.K., et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. Journal of Pharmacology and Experimental Therapeutics 1998, 286:447-458.
10. Heiskanen T., Heiskanen T., Kairemo K. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. Current Pharmaceutical Design 2009, 15:988-1007.
11. Kletting P., Kull T., Bunjes D., Mahren B., Luster M., Reske S.N., et al. Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model. Journal of Nuclear Medicine 2010, 51:484-491.
12. Lendvai G., Velikyan I., Estrada S., Erikssin B., Langstrom B., Bergstrom M. Biodistribution of 68Ga-labelled LNA-DNA mixmer antisense oligonucleotides for rat chromagranin-A. Oligonucleotides 2008, 18:33-49.
13. Mahato R.I., Narang A.S., Thoma L., Miller D.D. Emerging trends in oral delivery of peptide and protein drugs. Critical Reviews in Therapeutic Drug Carrier Systems 2003, 20:153-214.
14. Murphy R.E., Kinhikar A.G., Shields M.J., Del Rosario J., Preston R., Levin N., et al. Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. Journal of Pharmaceutical and Biomedical Analysis 2010, 53:221-227.
15. Peng B., Andrews J., Nestorov I., Brennan B., Nicklin P., Rowland M. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense & Nucleic Acid Drug Development 2001, 11:15-27.
16. Porter C.J., Edwards G.A., Charman S.A. Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Advanced Drug Delivery Reviews 2001, 50:157-171.
17. Richter W.F., Gallati H., Schiller C.-D. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metabolism and Disposition 1999, 27:21-25.
18. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nature Reviews Immunology 2007, 7:715-725.
19. Shah D.K., Betts A.M., Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Journal of Pharmacokinetics and Pharmacodynamics 2011, doi:(Epub ahead of print). 10.1007/2 10928-011-9232-2.
20. Strober W., Waldmann T.A. Role of the kidney in the metabolism of plasma proteins. Nephron 1974, 13:37-68.
21. Supersaxo A., Hein W.R., Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharmaceutical Research 1990, 7:167-169.
22. Tornoe C.W., Agerso H., Nielsen H.A., Madsen H., Jonsson E.N. Population pharmacokinetic modeling of a subcutaneous depot of GnRH antagonist degarelix. Pharmaceutical Research 2004, 21:574-584.
23. Touraine P., D'Souza G.A., Kourides I., Abs R., Barclay P., Xie R., et al. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. European Journal of Endocrinology 2009, 161:533-540.
24. 125 I]-labeled therapeutic proteins: application in protein drug development beyond oncology. Journal of Pharmaceutical Sciences 2010, 99:1028-1045.
25. Webster R., Xie R., Didier E., Finn R., Finnessy J., Edgington A., et al. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica 2008, 38:1340-1351.
26. Webster R., Elliott V., Park B.K., Walker D., Hankin M., Taupin P. PEG and PEG conjugates toxicity: towards an understanding of the the toxicity of PEG and its relevance to PEGylated biologicals. PEGylated Protein Drugs: Basic Science and Clinical Application 2009, 127-146. Birkhäuser Verlag. F.M. Veronese (Ed.).
27. Yu R.Z., Kim T.W., Hong A., Watanabe T.A., Gaus H.J., Geary R.S. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metabolism and Disposition 2007, 35:460-468.